Mergermarket Uncovers Some Interesting M&A Data

Take a look at Mergermarket’s Global Pharma, Medical & Biotech (PMB) trend report for the third quarter (Q3) of 2014. The full report is  HERE.

A few key findings include:

• Global Pharma, Medical & Biotech M&A activity saw the announcement of 869 deals worth US$354.3bn so far in 2014, already the highest annual level on Mergermarket record (since 2001) by value. The M&A deal value in the sector increased 169.8% from Q1-Q3 2013 (US$131.3bn) and 8.6% by volume. PMB is the second most active sector globally, following Energy, Mining & Utilities, with a 14.2% market share, the biggest portion since 2001.

• In Q3 2014 PMB deals totaled US$108.2bn, more than double the total value in Q3 2013 (US$ 50bn), and resulted in 2014 being the first year to see two quarters valued above US$ 100bn. Q3 2014 was down 43.6% from US$ 191.9bn-worth of deals in Q2 2014. Aside from the big ticket deals, deal count this year shows that even smaller deals are important for the activity in the sector seeing as 871 announcements.
• The big jump from last year is mainly due to the announcement of eight mega-deals (above US$ 10bn) amounting to a total of US$ 220.3bn, versus two announced in Q1-Q3 2013 totaling just US$ 27.4bn. The mega-deals alone accounted for 62.2% of the total activity in the sector, and represented 8.8% of total global M&A value.